Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Apellis Pharmaceuticals Inc (APLS) today and set a price target of $53. The company’s shares closed on Friday at $15.34.
Piros noted:
“We reiterate our OW rating. Apellis is developing APL-2, an investigational C3 inhibitor for complement-mediated diseases. In our view, APLS shares offer a compelling risk-reward profile due to the large market potential and compelling efficacy profile in PNH and geographic atrophy (GA). Valuation Summary We arrive at our 12-month price target of $53/share by assessing the after-tax, risk- adjusted NPV of potential future cash flows from APL-2.”
According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.9% and a 36.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apellis Pharmaceuticals Inc with a $41.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32 and a one-year low of $11.45. Currently, Apellis Pharmaceuticals Inc has an average volume of 262.9K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product.
